The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
about
Advances in the treatment of newly diagnosed glioblastomaIntegrating different data types by regularized unsupervised multiple kernel learning with application to cancer subtype discovery.Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumorsThe novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids.Combining immunotherapy with radiation for the treatment of glioblastoma.Toward precision medicine in glioblastoma: the promise and the challenges.Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.The Dynamics of Interactions Among Immune and Glioblastoma Cells.Novel chemotherapeutics and other therapies for treating high-grade glioma.An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma.Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade.Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas.Viability of glioblastoma stem cells is effectively reduced by diisothiocyanate-derived mercapturic acids
P2860
Q26773514-DA2F7A7C-5386-427E-8834-8BAB4EAC3895Q30971287-2BA7DE96-BBDB-467A-BCB5-48B10741C8DEQ36174719-96E2B8EE-34FE-4676-9C06-6CDAC36AE9EDQ36367252-1B77DE16-8923-4168-92FD-FCC9C75425F5Q37220522-13BB130A-4917-4490-8BE3-AE48348278AEQ37362563-FD73984D-AB66-4187-9477-A5D6CAE1544AQ37730054-CB15FE9C-3AF1-444B-A60C-374BD9A29BA0Q38422623-59F2D04F-7E21-4AD3-80F7-05625CEAB074Q38454659-2BD10C77-82E3-4C47-8712-1EA202E47F41Q38526550-EFD17564-6556-423C-B626-191AD3790C75Q38557236-2C41F1EA-CA4E-4B80-837F-B1608A706B1DQ38569802-EFFA1B13-B4B3-4A2B-B357-F3486B061D93Q38603909-6932E505-FE5F-49FC-AD00-1230611F7C4EQ38811271-D1EB22CB-4A1F-4A09-BCBD-11B35EC9BC32Q38873014-F5951D9F-3268-4634-B739-44426289EE7BQ38969029-5835C057-C7E1-42FB-A978-2EADE216B2B1Q55288869-5A831822-303D-4379-AB23-B4265C2AA4CFQ55456643-9ED50924-9E90-4584-BBD7-5956ECA43FADQ57788675-A1CB73F2-8DF9-46F1-9C90-545DF752BDFF
P2860
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
@en
type
label
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
@en
prefLabel
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
@en
P2093
P2860
P356
P1433
P1476
The future of glioblastoma therapy: synergism of standard of care and immunotherapy.
@en
P2093
Jacob Ruzevick
Jennifer E Kim
Michael Lim
Mira A Patel
P2860
P304
P356
10.3390/CANCERS6041953
P577
2014-09-29T00:00:00Z